Our group harnesses chemically induced-proximity (CIP) strategies to discover novel anticancer agents. These include, for example, PROTACs, which reprogram the cell’s ubiquitination machinery to selectively degrade disease-causing proteins via the proteasome. However, due to their size and complexity, such molecules exhibit unfavorable physicochemical characteristics. A central focus of our research is to characterize, understand, and ultimately optimize their properties. In parallel, we explore emerging CIP classes, such as transcriptional and epigenetic CIPs (TCIPs), which enable the targeting of transcription factors. Across both areas, we develop so-called molecular glues - more drug-like compounds that promote the formation of neomorphic protein-protein interactions.